Parkinson's Disease
Conditions
Keywords
Parkinson's Disease, Physical Activity, Mitochondrial Function, Skin Fibroblasts
Brief summary
The aim of this study is to investigate the effect of physical activity on mitochondrial function in skin fibroblasts in patients with Parkinson's disease.
Detailed description
A randomized double-blind clinical trial will be conducted to study the effects of physical activity on mitochondrial function in skin fibroblasts in patients with Parkinson's disease. It is an intervention study, and twenty-four patients will be needed. Once the subjects have been selected, they will be randomly assigned into three groups (eight patients in each group). The first group will perform basic physical training (BPT) based on strength and resistance, the second group will perform BPT combined with functional exercises (BPTFE) with cognitive and motor training, and the third group will not carry out any activity program, serving as control. The interventions will last 60 minutes, with a frequency of 3 times a week, during 16 weeks. The control group will receive 4 months of PA from the program that has obtained the best results,in terms of symptoms and quality of life, after the last evaluation.
Interventions
OTHERPhysical activity
This physical activity program will be based only on the work of basic physical training, in which specifically and mainly the strength and resistance will be worked, but also flexibility
usual clinical practice
Sponsors
University of Coimbra
Hospital Vall d'Hebron
University Ramon Llull
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
50 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* Patients with a medical diagnosis of idiopathic PD, Hoehn and Yahr scale stages of I-III. * Patients who score ≥26 on the Montreal Cognitive Assessment (MoCA). * Patients who have signed the IC. * Patients with stable medication. * Age between 50 and 70 years, and able to walk independently for 6 minutes.
Exclusion criteria
* Patients with a pathology other than idiopathic PD. * Patients with cognitive impairment (MoCA \<26 points). * Patients with uncontrolled cardiovascular disease, visual impairment, or recent musculoskeletal disorders in the extremities. * Patients who are performing another therapeutic exercise protocol. * Patients who have undergone surgery to influence any symptom from the PD.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in oxygen consumption rate | Beginning of the study and after 4 months | Oxygen uptake (VO2, mlkg-1min-1) measured by Seahorse XFe96 |
| Change in ATPmax levels | Beginning of the study and after 4 months | Maximal mitochondrial ATP production rates measured by Seahorse XFe96 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mobility | Beginning of the study, first visit | clinical performance-based measure of lower extremity function, mobility and fall risk, measured by the Timed Up and Go Test (TUG) questionnaire |
| Non-motor and motor function | Beginning of the study, first visit | non-motor and motor experiences of daily living and motor complications measured by the MDS-Sponsored Revision of the UPDRS (MDS-UPDRS) questionnaire |
| Mood | Beginning of the study, first visit | Intensity of depression in clinical and normal patients measured by the Beck Depression Inventory (BDI) questionnaire |
| Cognitive aspects | Beginning of the study, first visit | Cognitive aspects measured by the Montreal Cognitive Assessment scale (MoCA) |
| Sleepiness | Beginning of the study, first visit | Self-administered questionnaire with 8 questions measured by the Epworth Sleepiness Scale (ESS) questionnaire |
Countries
Spain
Outcome results
None listed